» Articles » PMID: 23351552

A High-content, Live-cell, and Real-time Approach to the Quantitation of Ligand-induced β-Arrestin2 and Class A/Class B GPCR Mobilization

Overview
Date 2013 Jan 29
PMID 23351552
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

We report the development of a method to analyze receptor and β-arrestin2 mobilization between Class A and B GPCRs via time-resolved fluorescent microscopy coupled with semiautomated high-content multiparametric analysis. Using transiently expressed, tagged β2-adrenergic receptor (β₂-AR) or parathyroid hormone receptor type 1 (PTH₁R), we quantified trafficking of the receptors along with the mobilization and colocalization of coexpressed tagged β-arrestin2. This classification system allows for exclusion of cells with nonoptimal characteristics and calculation of multiple morphological and spatial parameters including receptor endosome formation, β-arrestin mobilization, colocalization, areas, and shape. Stimulated Class A and B receptors demonstrate dramatically different patterns with regard to β-arrestin interactions. The method provides high kinetic resolution measurement of receptor translocation, which allows for the identification of the fleeting β-arrestin interaction found with β₂-AR agonist stimulation, in contrast to stronger mobilization and receptor colocalization with agonist stimulation of the PTH₁R. Though especially appropriate for receptor kinetic studies, this method is generalizable to any dual fluorescence probe system in which quantification of object formation and movement is desired. These methodologies allow for quantitative, unbiased measurement of microscopy data and are further enhanced by providing real-time kinetics.

Citing Articles

β-PIX cooperates with GIT1 to regulate endothelial nitric oxide synthase in sinusoidal endothelial cells.

Liu S, Premont R, Park K, Rockey D Am J Physiol Gastrointest Liver Physiol. 2022; 323(5):G511-G522.

PMID: 36044673 PMC: 9639759. DOI: 10.1152/ajpgi.00034.2022.


Asymmetric Recruitment of β-Arrestin1/2 by the Angiotensin II Type I and Prostaglandin F2α Receptor Dimer.

Fillion D, Devost D, Sleno R, Inoue A, Hebert T Front Endocrinol (Lausanne). 2019; 10:162.

PMID: 30936850 PMC: 6431625. DOI: 10.3389/fendo.2019.00162.


Translating in vitro ligand bias into in vivo efficacy.

Luttrell L, Maudsley S, Gesty-Palmer D Cell Signal. 2017; 41:46-55.

PMID: 28495495 PMC: 5675828. DOI: 10.1016/j.cellsig.2017.05.002.


S1P in HDL promotes interaction between SR-BI and S1PR1 and activates S1PR1-mediated biological functions: calcium flux and S1PR1 internalization.

Lee M, Appleton K, El-Shewy H, Sorci-Thomas M, Thomas M, Lopes-Virella M J Lipid Res. 2016; 58(2):325-338.

PMID: 27881715 PMC: 5282949. DOI: 10.1194/jlr.M070706.


The conformational signature of β-arrestin2 predicts its trafficking and signalling functions.

Lee M, Appleton K, Strungs E, Kwon J, Morinelli T, Peterson Y Nature. 2016; 531(7596):665-8.

PMID: 27007854 PMC: 4973468. DOI: 10.1038/nature17154.


References
1.
Dorval T, Ogier A, Genovesio A, Lim H, Kwon D, Lee J . Contextual automated 3D analysis of subcellular organelles adapted to high-content screening. J Biomol Screen. 2010; 15(7):847-57. DOI: 10.1177/1087057110374993. View

2.
Bockaert J, Perroy J, Becamel C, Marin P, Fagni L . GPCR interacting proteins (GIPs) in the nervous system: Roles in physiology and pathologies. Annu Rev Pharmacol Toxicol. 2010; 50:89-109. DOI: 10.1146/annurev.pharmtox.010909.105705. View

3.
Wills L, Trager R, Beeson G, Lindsey C, Peterson Y, Beeson C . The β2-adrenoceptor agonist formoterol stimulates mitochondrial biogenesis. J Pharmacol Exp Ther. 2012; 342(1):106-18. PMC: 3383035. DOI: 10.1124/jpet.112.191528. View

4.
Hudson C, Oakley R, Sjaastad M, Loomis C . High-content screening of known G protein-coupled receptors by arrestin translocation. Methods Enzymol. 2006; 414:63-78. DOI: 10.1016/S0076-6879(06)14005-7. View

5.
Hanyaloglu A, Von Zastrow M . Regulation of GPCRs by endocytic membrane trafficking and its potential implications. Annu Rev Pharmacol Toxicol. 2008; 48:537-68. DOI: 10.1146/annurev.pharmtox.48.113006.094830. View